Actively Recruiting
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Led by Y-mAbs Therapeutics · Updated on 2024-10-02
60
Participants Needed
8
Research Sites
228 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
CONDITIONS
Official Title
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent from patient or legal guardian as required
- Age 18 years or older (16 years or older for High Risk Neuroblastoma and Sarcoma) at time of consent
- Measurable disease based on RECIST 1.1 criteria
- ECOG performance status of 0 or 1
- Expected survival greater than 3 months
- Platelet counts at least 100,000 cells/mm3
- Hemoglobin at least 9 g/dL
- Adequate kidney function with serum creatinine 1.5 mg/dL or less or creatinine clearance at least 60 mL/min
- Ability and willingness to follow the trial protocol
You will not qualify if you...
- Chemotherapy, radiotherapy, immunotherapy, or major surgery within 3 weeks before first treatment dose
- Receiving any other investigational cancer therapy within 3 weeks before first treatment dose
- Ongoing radiation toxicity from previous radiation therapy
- Diagnosis of autoimmune disease, immunodeficiency, or active infection with HIV, hepatitis B or C
- Previous treatment with anti-GD2 antibody
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
HonorHealth
Scottsdale, Arizona, United States, 85258
Actively Recruiting
2
City of Hope National Medical Center
Duarte, California, United States, 91010
Actively Recruiting
3
University of Chicago
Chicago, Illinois, United States, 60637
Not Yet Recruiting
4
Corewell Health-BAMF Health
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
5
Memorial Sloan- Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
6
Case Western Reserve University, Cleveland
Cleveland, Ohio, United States, 44106
Actively Recruiting
7
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15260
Active, Not Recruiting
8
University of Wisconsin-Madison
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
J
Joris Wilms
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here